« Return to News | Awards & Advancement

CRA honored with 5 STEVIE Awards

Friday, June 22, 2012 02:05 PM

Tempe, Ariz.-based Clinical Research Advantage, a community-based network of clinical trial sites, was honored with three silver and two bronze STEVIE Awards at the 10th Annual American Business Awards on June 18. 

Clinical Research Advantage received the following awards:

  • The silver award for “Company of the Year” in the pharmaceuticals category
  • A bronze award for the “Fastest-Growing Company of the Year” in the pharmaceuticals category
  • David Bruggeman, CRA’s president and COO, was honored with silver awards for “Executive of the Year” in both the pharmaceuticals and the health products and services categories
  • Casey Orvin, CRA’s vice president of business development, and Amanda Drake, CRA’s director of business development, were honored with a bronze award for “Management Team of the Year” in the pharmaceuticals category

The American Business Awards are the nation’s premier business awards program. This year, more than 3,000 nominations from organizations of all sizes and in virtually every industry were submitted for consideration in a wide range of categories.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.